{"id":27159,"date":"2021-05-28T09:08:55","date_gmt":"2021-05-28T07:08:55","guid":{"rendered":"https:\/\/www.satt.fr\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/"},"modified":"2021-05-28T09:08:55","modified_gmt":"2021-05-28T07:08:55","slug":"la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/","title":{"rendered":"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique"},"content":{"rendered":"<p><strong>Afin d\u2019avancer le d\u00e9veloppement clinique de son dispositif m\u00e9dical d\u2019extraction sp\u00e9cifique de m\u00e9taux libres toxiques du sang, la Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, annonce lever 5,75 millions d\u2019euros. Ce tour de table rassemble deux investisseurs institutionnels, Arbevel et Kreaxi, ainsi que le fonds French Tech Seed op\u00e9r\u00e9 pour le compte de l\u2019Etat par Bpifrance dans le cadre du Programme d\u2019investissements d\u2019avenir (PIA), qui r\u00e9alise son premier investissement en fonds propres ainsi que des investisseurs priv\u00e9s r\u00e9unis autour de Buffavent Holding.<\/strong><\/p>\n<p>Cr\u00e9\u00e9e fin 2017, MexBrain est une Medtech sp\u00e9cialis\u00e9e dans le contr\u00f4le et l\u2019extraction de m\u00e9taux exc\u00e9dentaires pr\u00e9sents dans l\u2019organisme. Elle a con\u00e7u un dispositif m\u00e9dical d\u2019extraction de cations m\u00e9talliques toxiques, combinant polym\u00e8res, ch\u00e9latants et dialyse, technologie qui conf\u00e8re une plus grande rapidit\u00e9 d\u2019extraction, une meilleure sp\u00e9cificit\u00e9 et quantit\u00e9 extraite.<\/p>\n<p>Ces nouveaux fonds lev\u00e9s aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi seront ainsi d\u00e9di\u00e9s \u00e0 l\u2019entr\u00e9e en clinique des cas les plus critiques de la maladie de Wilson et au d\u00e9veloppement pr\u00e9-clinique dans de nombreuses autres pathologies.<\/p>\n<p>Les m\u00e9taux libres en exc\u00e8s (cuivre, fer, plomb\u2026), aggravent l\u2019\u00e9tat de sant\u00e9 des patients et entra\u00eenent fr\u00e9quemment des d\u00e9faillances d\u2019organes multiples. Dans le cas de la maladie de Wilson, maladie g\u00e9n\u00e9tique orpheline, un exc\u00e8s de cuivre provoque des d\u00e9gradations h\u00e9patiques et neurologiques graves, allant jusqu\u2019\u00e0 la transplantation ou au d\u00e9c\u00e8s. MexBrain propose ainsi son proc\u00e9d\u00e9 pour l\u2019extraction s\u00e9lective de ce m\u00e9tal.<\/p>\n<p>L\u2019extraction rapide, sp\u00e9cifique et s\u00e9curis\u00e9e des m\u00e9taux en exc\u00e8s pourrait \u00e9galement fournir une solution adapt\u00e9e pour limiter l\u2019hospitalisation et la mortalit\u00e9 des patients dans de nombreuses autres indications : h\u00e9mochromatose, an\u00e9mies h\u00e9molytiques, transplantation, insuffisance r\u00e9nale ou h\u00e9patique aigu\u00eb, endom\u00e9triose, septic\u00e9mie&#8230; Dans les services de soins intensifs o\u00f9 elle peut \u00eatre facilement d\u00e9ploy\u00e9e, la technologie MexBrain servira de traitement proactif en neutralisant les m\u00e9taux lib\u00e9r\u00e9s avant qu\u2019ils ne causent des dommages et n\u2019entra\u00eenent notamment des insuffisances graves, en particulier pour les reins, le foie et les poumons.<\/p>\n<p><em>\u00ab MexBrain est heureux de recevoir \u00e0 son capital des investisseurs sp\u00e9cialis\u00e9s en sant\u00e9 pour financer l\u2019entr\u00e9e en clinique de son proc\u00e9d\u00e9 d\u2019ici un an et l\u2019\u00e9tendre \u00e0 d\u2019autres indications majeures en parall\u00e8le. \u00bb<\/em>, d\u00e9clare <strong>Thomas Brichart, Directeur G\u00e9n\u00e9ral de MexBrain.<\/strong><\/p>\n<p><em>\u00ab Les m\u00e9taux, sous leurs diff\u00e9rentes formes, se trouvent au coeur de nombreux m\u00e9canismes biologiques. Le contr\u00f4le fin de leur hom\u00e9ostasie est crucial, nous avons devant nous de nombreuses perspectives de traitement.\u00bb<\/em>, compl\u00e8te <strong>Pr. Olivier Tillement, Universit\u00e9 Lyon 1, cofondateur de MexBrain.<\/strong><\/p>\n<p><em>\u00ab Arbevel est fier d\u2019\u00eatre l\u2019investisseur leader de cette S\u00e9rie A de MexBrain. La d\u00e9monstration en clinique de la performance du dispositif est cl\u00e9 pour la cr\u00e9ation de valeur et le futur de l\u2019entreprise. \u00bb<\/em>, commente <strong>Marc Le Bozec, g\u00e9rant du fonds Arbevel Life Sciences Crossover I.<\/strong><\/p>\n<p><em>\u00ab Pour le premier investissement en capital du fonds French Tech Seed, Bpifrance est fier d\u2019accompagner MexBrain, p\u00e9pite de la Deeptech. Nous avons \u00e9t\u00e9 s\u00e9duits par l\u2019\u00e9tendue des indications possibles de sa technologie et sa facilit\u00e9 d\u2019int\u00e9gration dans des machines de dialyse d\u00e9j\u00e0 existantes, ce qui permet une grande facilit\u00e9 de d\u00e9ploiement dans les h\u00f4pitaux et cliniques \u00bb<\/em>, souligne <strong>Emmanuel Audouard, Directeur du P\u00f4le Investissements Transverses Capital-Risque chez Bpifrance.<\/strong><\/p>\n<p><em>\u00ab Investisseur r\u00e9gional de r\u00e9f\u00e9rence, Kreaxi est ravi de participer au financement du d\u00e9veloppement de MexBrain, fruit de l\u2019innovation m\u00e9dicale soutenue depuis des d\u00e9cennies par la r\u00e9gion lyonnaise \u00bb<\/em>, ajoute <strong>Sandra Dubos, investisseur chez Kreaxi.<\/strong><\/p>\n<p><strong><span style=\"color: #ff6600;\">A propos de MexBrain<\/span><\/strong><\/p>\n<p>Spin-off de l\u2019Universit\u00e9 de Lyon, MexBrain a \u00e9t\u00e9 cr\u00e9\u00e9e en 2017 par plusieurs chercheurs dont Olivier Tillement (Professeur \u00e0 l\u2019Universit\u00e9 Lyon 1 et co-fondateur de la soci\u00e9t\u00e9 NHTheraguix) dans le but de combiner des technologies de dialyse et de captation des m\u00e9taux pour la purification de syst\u00e8mes biologiques de m\u00e9taux toxiques. La start-up a pour objectif d\u2019ouvrir la voie \u00e0 une nouvelle m\u00e9thode de traitement des intoxications m\u00e9talliques impliqu\u00e9es dans de nombreuses pathologies. L\u2019\u00e9quipe de MexBrain compte \u00e0 ce jour 8 personnes. MexBrain a \u00e9t\u00e9 soutenue depuis sa cr\u00e9ation par l\u2019Institut Lumi\u00e8re Mati\u00e8re (Universit\u00e9 Claude Bernard Lyon 1 \/ CNRS) dont elle est issue, PULSALYS ainsi que la r\u00e9gion Auvergne-Rh\u00f4ne-Alpes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Afin d\u2019avancer le d\u00e9veloppement clinique de son dispositif m\u00e9dical d\u2019extraction sp\u00e9cifique de m\u00e9taux libres toxiques du sang, la Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, annonce lever 5,75 millions d\u2019euros. Ce tour de table rassemble deux investisseurs institutionnels, Arbevel et Kreaxi, ainsi que le fonds French Tech Seed op\u00e9r\u00e9 pour le compte de l\u2019Etat par Bpifrance dans le cadre du Programme d\u2019investissements d\u2019avenir (PIA), qui r\u00e9alise son premier investissement en fonds propres ainsi que des investisseurs priv\u00e9s r\u00e9unis autour de Buffavent Holding.<\/p>\n","protected":false},"author":24,"featured_media":27160,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568,604],"tags":[],"class_list":["post-27159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en","category-startup-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sylvain DUC\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/\"},\"author\":{\"name\":\"Sylvain DUC\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"headline\":\"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique\",\"datePublished\":\"2021-05-28T07:08:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/\"},\"wordCount\":822,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg\",\"articleSection\":[\"News\",\"Success Stories\",\"Start-up\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/\",\"url\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/\",\"name\":\"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg\",\"datePublished\":\"2021-05-28T07:08:55+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg\",\"width\":760,\"height\":520},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\",\"name\":\"Sylvain DUC\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/sylvain\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/","twitter_misc":{"Written by":"Sylvain DUC","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/"},"author":{"name":"Sylvain DUC","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"headline":"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique","datePublished":"2021-05-28T07:08:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/"},"wordCount":822,"image":{"@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg","articleSection":["News","Success Stories","Start-up"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/","url":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/","name":"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg","datePublished":"2021-05-28T07:08:55+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mexbrain.jpg","width":760,"height":520},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/la-medtech-lyonnaise-mexbrain-boostee-par-pulsalys-leve-pres-de-6-millions-deuros-aupres-darbevel-du-fonds-french-tech-seed-et-de-kreaxi-pour-developper-son-dispositif-medical-en\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"La Medtech lyonnaise MexBrain, boost\u00e9e par PULSALYS, l\u00e8ve pr\u00e8s de 6 millions d\u2019euros aupr\u00e8s d\u2019Arbevel, du fonds French Tech Seed et de Kreaxi pour d\u00e9velopper son dispositif m\u00e9dical en clinique"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca","name":"Sylvain DUC","url":"https:\/\/www.satt.fr\/en\/author\/sylvain\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/27159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=27159"}],"version-history":[{"count":0,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/27159\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/27160"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=27159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=27159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=27159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}